The consensus estimate for Q1 2026 revenue is $6.98 billion, and the earnings are expected to come in at $0.33 per share. The full year 2026's revenue is expected to be $30.16 billion and the earnings ...
A newly approved pill form of GLP-1 medication is giving patients an alternative to injections, marking a significant shift in how doctors may treat obesity and related conditions. Dr. Ellen Schur, an ...
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. The medical device market is expected to grow to almost $800 ...
Common GLP-1s include semaglutides like Ozempic and Wegovy, and tirzepatides like Zepbound and Mounjaro. These drugs work by mimicking a natural hormone to regulate appetite, blood sugar, and feelings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results